By Maryanne Demasi at Brownstone dot org.

Yesterday, I took part in a panel discussion in Washington, D.C., on the weaponisation of science - specifically, how conflicts of interest, industry influence, and scientific deception have reshaped modern medicine.

It was an important conversation about how the scientific process has been hollowed out by financial incentives, regulatory capture, and institutional cowardice.

For me, this is not an abstract debate. I've spent much of my career investigating how science becomes distorted - not by a few rogue actors, but through an entire system built on commercial dependence.

Once you start pulling the threads of how evidence is produced, who funds it, who controls the data, and who polices the outcomes, you quickly realise that the corruption of science is structural and systemic.

The Statin Wars: A Case Study in Deception

I first saw this clearly while investigating cholesterol-lowering drugs. My 2013 Catalyst documentary questioned whether statins were being overprescribed, and it unleashed a media firestorm.

The episode was pulled after industry outrage, and I was publicly attacked. None of the critics engaged with the evidence - they simply sought to silence it.

In 2018, I published a narrative review, "Statin wars: have we been misled by the evidence?"

The piece revealed that the raw data underpinning statin trials were held exclusively by the Oxford-based Cholesterol Treatment Trialists (CTT) Collaboration and had never been released.

The CTT group had signed confidentiality agreements with pharmaceutical sponsors, blocking independent access to the raw data and preventing verification.

Yet those same meta-analyses have shaped prescribing guidelines around the world - produced by a group that sits under Oxford's Clinical Trial Service Unit, which receives millions in funding from statin manufacturers.

In my public talks, I've described the statin story as a case study in bias and censorship. The trials used well-worn techniques to amplify benefits and minimise harms.

For example, they use 'run-in' periods before the trial to weed out people who couldn't tolerate the drug, thereby artificially lowering the adverse events detected during the trial.

Often the outcomes were reported in relative, not absolute, terms - effectively exaggerating benefits that were, in reality, minuscule to the individual patient.

The vast majority of statin trials are funded by the manufacturers, and almost all show benefit - except for one publicly funded study that showed the opposite.

So, who funds the trial matters. The system is captured, plain and simple.

Regulatory Capture and the Illusion of Oversight

The same dynamics pervade drug regulation. In a 2022 BMJ investigation, I showed how drug regulators rely heavily on funding from the very industries they oversee.

In Australia, the Therapeutic Goods Administration derives 96% of its operating budget from industry fees.

In the US, the same conflict exists through the Prescription Drug User Fee Act (PDUFA), which allows the FDA to collect billions from drug companies.

Those "user fees" now fund roughly two-thirds of the agency's drug-review budget - a structural conflict of interest described by one scholar as "institutional corruption."

And it's true.

Industry money drives the demand for faster approvals through "expedited pathways," which often means weaker evidence, shorter trials, and looser post-marketing obligations.

Regulators defend this as "innovation," yet the drugs approved under these pathways are far more likely to later receive black-box warnings or be withdrawn from the market due to safety issues.

The result is a system that rewards speed and sales over safety and substance.

The illusion of effective drugs has become even clearer thanks to a landmark investigation this year by Jeanne Lenzer and Shannon Brownlee.

They reviewed more than 400 FDA drug approvals between 2013 and 2022, and found that 73% of the drugs failed to meet fo...